Loading...
Market
Main competitor to Asciminib (Scemblix) in US by end of 2025?
2
Resolution / Starting Odds
Bristol-Myers Squibb • 25%
Pfizer • 25%
Roche • 25%
Other • 25%
Market analysis reports and competitive landscape studies published by industry analysts
Story
FDA Grants Accelerated Approval for Novartis's Asciminib (Scemblix) for CML, 25% Major Molecular Response Rate
Oct 29, 2024, 05:35 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Novartis's asciminib (brand name Scemblix) as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Clinical trials demonstrated a 25% major molecular response rate at 24 weeks for asciminib, compared to 13% for the previous standard treatment, bosutinib. This approval positions asciminib as a promising option for frontline therapy in this patient population. Further application reviews are ongoing with other regulatory agencies, including Health Canada.
View original story
Similar markets
Bristol-Myers Squibb • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Verzenio (abemaciclib) • 25%
Kisqali (ribociclib) • 25%
Enhertu (trastuzumab deruxtecan) • 25%
Other • 25%
Takeda • 25%
Amgen • 25%
Novo Nordisk • 25%
Other • 25%
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Novartis • 25%
Gilead Sciences • 25%
Bristol Myers Squibb • 25%
Other • 25%
Launch new competing drug • 25%
Increase marketing for existing drugs • 25%
File a lawsuit or regulatory complaint • 25%
No significant response • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
Aucatzyl (Autolus Therapeutics) • 25%
Kymriah (Novartis) • 25%
Yescarta (Gilead) • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Yes • 50%
No • 50%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Pfizer • 25%
Moderna • 25%
Roche • 25%
Other • 25%